Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Increase in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 67,400 shares, an increase of 6.3% from the March 15th total of 63,400 shares. Based on an average daily volume of 24,900 shares, the short-interest ratio is presently 2.7 days. Approximately 9.0% of the company’s shares are sold short.

Bio-Path Price Performance

BPTH traded up $0.12 during trading on Tuesday, reaching $3.06. 9,729 shares of the stock traded hands, compared to its average volume of 24,398. Bio-Path has a fifty-two week low of $2.71 and a fifty-two week high of $44.80. The stock’s 50-day simple moving average is $5.84 and its two-hundred day simple moving average is $8.63. The stock has a market cap of $2.08 million, a price-to-earnings ratio of -0.08 and a beta of 0.36.

Bio-Path (NASDAQ:BPTH) last posted its earnings results on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same quarter last year, the firm earned ($10.60) earnings per share. Research analysts anticipate that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. StockNews.com assumed coverage on Bio-Path in a report on Tuesday. They issued a “sell” rating on the stock. Roth Mkm upped their price objective on shares of Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 27th.

Institutional Investors Weigh In On Bio-Path

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Bio-Path by 77.5% during the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares during the last quarter. Walleye Capital LLC acquired a new position in Bio-Path in the 3rd quarter valued at $77,000. Citadel Advisors LLC bought a new position in Bio-Path in the 3rd quarter worth $35,000. Renaissance Technologies LLC acquired a new position in Bio-Path during the 2nd quarter worth $70,000. Finally, Virtu Financial LLC acquired a new position in Bio-Path during the 1st quarter worth $38,000. 5.74% of the stock is currently owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.